openPR Logo
Press release

With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 World ADC Summit

11-13-2024 07:30 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: PRChoices
With Knockout ADC Innovations, Creative Biolabs Took Center

Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology.
New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to ADC research and innovation. With plans already confirmed for participation in 2025, Creative Biolabs extended an open invitation to industry peers to engage and explore partnership opportunities that drive transformative outcomes in antibody-drug conjugate discovery [https://www.creative-biolabs.com/adc/one-stop-adc-development-service.htm].

Image: https://www.getnews.info/uploads/5920b1d6b54212953051489d2b14f144.png

"At this year's World ADC, we demonstrated one-stop ADC development, a comprehensive suite that addresses the industry's evolving needs from target identification and antibody engineering to linker-payload optimization and process development," one of the delegates says, "which, as a holistic approach, enables clients to streamline their development timelines, reducing risks, and accelerating delivery from the bench to the bedside."

One of their most notable services is their bioconjugation chemistry service [https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm], which offers advanced antibody design and conjugation options to create ADCs that are stable, specific, and effective. The meticulous design of antibody linkages and conjugation techniques is critical in crafting ADCs that effectively deliver payloads to target cells while minimizing off-target effects.

Another of Creative Biolabs' defining strengths is their pioneering work in ADC payloads [https://www.creative-biolabs.com/adc/drug-module.htm] and linker chemistry, of which the custom payload solutions cater to diverse ADC applications, leveraging a wide selection of cytotoxic agents designed for highly targeted therapeutic impact. Furthermore, Creative Biolabs' linker technology is equally critical, as stable and cleavable linkers ensure that payloads are delivered precisely to target sites without compromising efficacy or safety. This proficiency empowers clients to confront some of ADC development's most daunting challenges, like toxicity management and potency optimization.

In addition, with a specialized ADC linker module [https://www.creative-biolabs.com/adc/linker-module.htm], Creative Biolabs continues to innovate in linker-payload systems that are crucial for maximizing ADC stability in systemic circulation and enhancing therapeutic payload release at the tumor site.

"The combination of well-engineered payloads and linkers strengthens the clinical potential of ADCs, translating research breakthroughs into actionable therapies." The delegate explains.

As 2024 progresses, Creative Biolabs is poised to expand its presence at two final key events-the Scientist Solution Vendor Event - NIH 37 and the Antibody Engineering & Therapeutics (US) conference in December. Through these platforms, Creative Biolabs seeks to further its mission to collaborate, innovate, and advance antibody-based solutions.

"These events offer invaluable opportunities for in-depth exchanges with leading scientists and industry partners, solidifying our commitment to pushing the boundaries of antibody-drug conjugate technology." Says the delegate.

To learn more about Creative Biolabs' cutting-edge services in ADC discovery, bioconjugation chemistry, payload development, and linker technology, visit their website at: https://www.creative-biolabs.com/adc.

About

As ADCs continue their transformation of the oncology landscape, Creative Biolabs offers an all-encompassing ADC discovery and development service to support clients in bringing innovative therapies from the lab bench to patient bedside.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=with-knockout-adc-innovations-creative-biolabs-took-center-stage-at-the-2024-world-adc-summit]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/adc



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 World ADC Summit here

News-ID: 3734076 • Views:

More Releases from Getnews

$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA)
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior …
Image: https://www.globalnewslines.com/uploads/2026/04/1776342906.jpg $KALA AI Platforms Enable Biotechs to Leverage Institutional-Grade AI Without Surrendering Control of Key Intellectual Property * Clinical-Stage Biopharmaceutical Company Building a Dedicated, On-Premises AI Infrastructure Platform for the Biotechnology Industry. * Initiative to be a Dedicated AI Infrastructure Partner for the Biotech Industry with On-Premises AI Systems Where Proprietary Data Never Leaves Client Control. * Platform-as-a-Service Model to Generate Recurring Revenue by Licensing AI Capabilities Where Top 20 Pharma Companies Invested
TXOne Networks Previews Stellar Discover: Safe OT Endpoint Visibility Without Disrupting Operations
TXOne Networks Previews Stellar Discover: Safe OT Endpoint Visibility Without Di …
A new detection-only endpoint sensor delivers asset inventory, vulnerability assessment, and security insights to OT environments with zero system interference. Image: https://www.globalnewslines.com/uploads/2026/04/8cb25dc7895a6ea124acd9d2b305c1dd.jpg Taipei - April 17th, 2026 - TXOne Networks, the operations-first OT security partner, today previewed Stellar Discover, a lightweight endpoint sensor designed to bring asset visibility and vulnerability assessment to OT environments where traditional approaches have proven difficult to deploy. Stellar Discover strengthens the early stages of TXOne's OT security
Joe W Boyou Sr Delivers HighStakes Aviation Thriller with Antonov225
Joe W Boyou Sr Delivers HighStakes Aviation Thriller with Antonov225
Image: https://www.globalnewslines.com/uploads/2026/04/1776360123.jpg Image: https://www.aionewswire.com/storage/images/ckeditor//61Y8eRwf6tL._SL1360__1776357837.jpg A powerful new release from Joe W. Boyou Sr., Antonov-225 [https://www.amazon.com/Antonov-225-Joe-W-Boyou-Sr/dp/1965552595/ref=sr_1_1?crid=E33OVX448J9O&&dib=eyJ2IjoiMSJ9.0S47Fy3a62N_dWg3YM3__w.AHyopcuaqyZpnVir17WanpJPXFr0Ty7M5NvG-trc7hU&&dib_tag=se&&keywords=Antonov+225+Joe+W.+Boyou+Sr.&&qid=1768594490&&s=books&&sprefix=antonov+225+joe+w.+boyou+sr.%2Cstripbooks-intl-ship%2C280&&sr=1-1], takes readers into the heart of modern conflict through a gripping blend of aviation, espionage, and survival. Inspired by real-world events, the novel captures the intensity of war while highlighting the resilience of those who stand against oppression. Set against the backdrop of the Ukraine and Russia conflict, Antonov-225 [https://www.amazon.com/Antonov-225-Joe-W-Boyou-Sr/dp/1965552595/ref=sr_1_1?crid=E33OVX448J9O&&dib=eyJ2IjoiMSJ9.0S47Fy3a62N_dWg3YM3__w.AHyopcuaqyZpnVir17WanpJPXFr0Ty7M5NvG-trc7hU&&dib_tag=se&&keywords=Antonov+225+Joe+W.+Boyou+Sr.&&qid=1768594490&&s=books&&sprefix=antonov+225+joe+w.+boyou+sr.%2Cstripbooks-intl-ship%2C280&&sr=1-1] follows Harvey, a United States Air Force pilot
Dr Geraldine Norman Hill Encourages Readers to Trust God Through Lifes Trials in Keeping the Faith in the Midst of Every Storm
Dr Geraldine Norman Hill Encourages Readers to Trust God Through Lifes Trials in …
Image: https://www.globalnewslines.com/uploads/2026/04/1776359861.jpg Faith often becomes most meaningful during life's most difficult moments. In her inspiring new book, Keeping the Faith in the Midst of Every Storm [https://www.amazon.com/KEEPING-FAITH-Midst-Every-Storm-ebook/dp/B0DX8C1QR9/ref], Dr. Geraldine Norman Hill [https://geraldinenhill.com/] shares a powerful message of perseverance, spiritual trust, and unwavering belief in God's promises. Drawing from personal experiences and a lifetime of faith, Dr. Hill offers readers encouragement and guidance for navigating life's challenges with confidence in God's plan. In

All 5 Releases


More Releases for ADC

ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments. Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion Key
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates. New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313. Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg "2023
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment. On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023 Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends. This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering National Semiconductor Nippon Precision Circuits Inc Micro Analog systems Microchip Technology. TelCom Semiconductor, Inc Vishay Siliconix Texas
ADC African Development Corporation GmbH & Co. KGaA: ADC exits shareholding in E …
ADC African Development Corporation (ADC), ISIN DE000A1E8NW9, a fast growing financial services group focusing on the frontier markets of sub-Saharan Africa, has successfully negotiated an exit for its 11.5% shareholding in Ecobank Zimbabwe for USD 5.2 million equaling approx. EUR 4.0 million. As of 30 September 2011, ADC had valued its shareholding in Ecobank Zimbabwe at EUR 1.25 million, so this transaction results in a realized profit of EUR 2.75